Overview

PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCC

Status:
Active, not recruiting
Trial end date:
2021-10-12
Target enrollment:
Participant gender:
Summary
Non-invasive imaging of tumor PD-L1 expression with 89Zr-labeled durvalumab PET/CT predicts response to durvalumab.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Radboud University
Collaborator:
AstraZeneca
Treatments:
Antibodies, Monoclonal
Durvalumab